Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ViiV Healthcare

A new at-home test will soon be available for chlamydia and gonorrhoea. Here’s what to know

Australia’s Therapeutic Goods Administration (TGA) has recently approved a self-test kit for chlamydia and gonorrhoea for women and other people with a vagina.

The Conversation

People with HIV offered hope of self-injected drug at home

People with HIV offered hope of self-injected drug at home

GSK-controlled company works on developing patient-administered treatment by end of the decade

The Guardian - UK

Gareth Thomas takes on gruelling Three Peaks challenge as fight to Tackle HIV stigma continues across the UK

Gareth Thomas takes on gruelling Three Peaks challenge as fight to Tackle HIV stigma continues across the UK

The Welsh rugby legend will be joined on the Three Peaks by some well-known celebrity supporters, partners from the Terrence Higgins Trust and ViiV Healthcare. as well as Tackle HIV advocates, some of whom are living with HIV

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Monkeypox: latest data reveals how the virus has affected women and non-binary people

Since May 2022, a global outbreak of human monkeypox infections has been reported in over 78,000 people. So far, infections have overwhelmingly occurred in sexually active men who have sex with men.

The Conversation

Gareth Thomas thanks ViiV for support in fight against HIV stigma

Gareth Thomas visited GSK House in his latest stop on the Myth Bus Tour.

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

FDA Approves ViiV Healthcare's Cabenuva For Virologically Suppressed Adolescents With HIV

The FDA has approved ViiV Healthcare's Cabenuva (cabotegravir, rilpivirine) for HIV-1 in virologically suppressed adolescents. The approval covers patients aged 12 years or older and weighing at least 35kg on a stable antiretroviral regimen, with no history of treatment failure and no known or suspected resistance to either cabotegravir or rilpivirine. The regimen…

inkl

Read news from The Economist, FT, and more,
with one subscription

Rugby legend Thomas encouraging people to get tested following Tackle HIV report

Rugby legend Thomas encouraging people to get tested following Tackle HIV report

Amid rugby union’s Six Nations tournament, Tackle HIV - a public awareness and education initiative in partnership with ViiV Healthcare and Terrence Higgins Trust - has released the Sex of our Nations report.

Deborah Waterhouse: ‘The HIV stigma remains, and this is a battle we’ve got to fight’

Deborah Waterhouse: ‘The HIV stigma remains, and this is a battle we’ve got to fight’

The GSK executive has found her niche at ViiV Healthcare developing HIV drugs, and is optimistic a cure will be found

The Guardian - UK

GSK To Get $1.25B As Settlement For HIV Treatment Drug Patent Row With Gilead

GSK To Get $1.25B As Settlement For HIV Treatment Drug Patent Row With Gilead

GlaxoSmithKline plc (NYSE: GSK) has settled a patent dispute between ViiV Healthcare and Gilead Sciences Inc (NASDAQ: GILD).

FDA Approves First Injectable For HIV Pre-Exposure Prevention - GSK, Pfizer Backed Treatment

FDA Approves First Injectable For HIV Pre-Exposure Prevention - GSK, Pfizer Backed Treatment

The FDA has approved ViiV Healthcare's Apretude (cabotegravir extended-release injectable suspension

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

Gilead Sciences Inc

Gilead Sciences

US Food and Drug Administration

Terrence Higgins Trust

Bristol Myers Squibb

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

384,597 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play